Skip to main content
CAPR
NASDAQ Life Sciences

Capricor's Deramiocel Shows Durable Five-Year Benefit in Duchenne Muscular Dystrophy, Bolstering FDA Review

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$27.5
Mkt Cap
$1.761B
52W Low
$4.3
52W High
$40.37
52W Position info
540% above low
Off High info
32% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $4.3.

Summary

Capricor Therapeutics announced new positive five-year data from its HOPE-2 Open-Label Extension study for Deramiocel in Duchenne Muscular Dystrophy (DMD), demonstrating attenuated disease progression and stable cardiac function. These long-term results, along with previously reported positive HOPE-3 Phase 3 data, will be presented at the PPMD 2026 Annual Conference. This comprehensive clinical evidence significantly strengthens the company's Biologics License Application (BLA) currently under FDA review. The positive data is crucial, especially given the recent lawsuit against its U.S. distributor that could impact commercialization. The FDA's PDUFA target action date for Deramiocel is August 22, 2026.

At the time of this announcement, CAPR was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.30 to $40.37. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 18, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $8.90 info
Change: +$0.130 (+1%) info
Market Cap: $488.975M info
CAPR
Nov 10, 2026, 5:25 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $8.90 info
Change: -$0.450 (-5%) info
Market Cap: $488.975M info
CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $8.90 info
Change: -$0.200 (-2%) info
Market Cap: $488.975M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $8.90 info
Change: -$0.0050 (-0.06%) info
Market Cap: $488.975M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $8.90 info
Change: -$0.183 (-2%) info
Market Cap: $488.975M info